Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. COO
7. QCOM
8. IRT
9. AEO
10. MSI

Go back to Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
(NASDAQ: XENE) Delayed: 58.98 -0.57 (0.96%)
Previous Close $59.55    52 Week High $9.75 
Open $59.04    52 Week Low $5.65 
Day High $59.81    P/E N/A 
Day Low $58.53    EPS $0.00 
Volume 489,445